Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cabaletta Bio, Inc. (CABA : NSDQ)

• Company Description    Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are in clinical stage. Cabaletta Bio Inc. is based in Philadelphia, United States. Number of Employees: 164

• Price / Volume Information    Yesterday's Closing Price: $1.57 Daily Weekly Monthly 20 Day Moving Average: 2,873,811 shares Shares Outstanding: 50.74 (millions) Market Capitalization: $79.67 (millions) Beta: 2.81 52 Week High: $8.77 52 Week Low: $0.99 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -16.04% -19.60% 12 Week 41.44% 16.26% Year To Date -30.84% -34.10%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2929 ARCH STREET SUITE 600 - PHILADELPHIA,PA 19104 USA ph: 267-759-3100 fax: - investors@cabalettabio.com http://www.cabalettabio.com

• General Corporate Information    Officers Steven Nichtberger - Chief Executive Officer and President Anup Marda - Chief Financial Officer Catherine Bollard - Director Scott Brun - Director Richard Henriques - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 12674W109 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 50.74 Most Recent Split Date: (:1) Beta: 2.81 Market Capitalization: $79.67 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.71 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.51 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.66 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -39.22% vs. Previous Quarter: -9.23% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/25 - -78.29 12/31/24 - -61.97 09/30/24 - -50.10 ROA 03/31/25 - -65.68 12/31/24 - -54.70 09/30/24 - -45.49 Current Ratio 03/31/25 - 3.96 12/31/24 - 6.15 09/30/24 - 8.11 Quick Ratio 03/31/25 - 3.96 12/31/24 - 6.15 09/30/24 - 8.11 Operating Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Net Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Pre-Tax Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Book Value 03/31/25 - 2.40 12/31/24 - 3.12 09/30/24 - 3.57 Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - 0.00 12/31/24 - 0.00 09/30/24 - 0.00 Debt-to-Capital 03/31/25 - 0.00 12/31/24 - 0.00 09/30/24 - 0.00

Powered by Zacks Investment Research ©